Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD:…
GlobalData’s latest analysis reveals that tezepelumab, evaluated in the Phase IIa COURSE trial, achieved a 26 per cent reduction…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.